Aspirin for Primary and Secondary Prevention of Cardiovascular Disease

被引：15
作者：
Godley, Robert W.
Hernandez-Vila, Eduardo
机构：
[1] Texas Heart Inst, Dept Cardiol, Houston, TX 77030 USA
[2] CHI St Lukes Hlth, Baylor St Lukes Med Ctr, 6624 Fannin St,Suite 2780, Houston, TX 77030 USA
来源：
TEXAS HEART INSTITUTE JOURNAL | 2016年 / 43卷 / 04期
关键词：
Anti-inflammatory agents; non-steroidal; aspirin/history/therapeutic use; history; 19th century; 20th century; myocardial infarction/prevention & control; platelet aggregation inhibitors; prevention; primary; secondary; stroke/prevention & control; vascular disease; LOW-DOSE ASPIRIN; TRIAL;
D O I：
10.14503/THIJ-16-5807
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：318 / 319
页数：2
相关论文
共 11 条
  • [1] Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE), BAYER HEALTHCARE
  • [2] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [3] British Heart Foundation, STUD CARD EV DIAB AS
  • [4] Calonge N, 2009, ANN INTERN MED, V150, P396
  • [5] Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT- D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
    De Berardis, Giorgia
    Sacco, Michele
    Evangelista, Virgilio
    Filippi, Alessandro
    Giorda, Carlo B.
    Tognoni, Gianni
    Valentini, Umberto
    Nicolucci, Antonio
    [J]. TRIALS, 2007, 8
  • [6] Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
    Grimm, R. H.
    McNeil, J. J.
    Applegate, W.
    Beilin, L.
    Espinoza, S.
    Johnston, C., I
    Kirpach, B.
    Margolis, K.
    Murray, A.
    Nelson, M. R.
    Reid, C. M.
    Shah, R.
    Storey, E.
    Tonkin, A. M.
    Wilson, P.
    Wolfe, R.
    Woods, R. L.
    Abhayaratna, W.
    Ames, D.
    Cobiac, L.
    Donnan, G.
    Gibbs, P.
    Head, R.
    Krum, H.
    Ives, D.
    Tonkin, A. M.
    Jelnik, M.
    Malik, M.
    Williamson, J.
    Eaton, C.
    Weissfeld, J.
    MacRae, F.
    Rodriguez, L. M.
    Newman, A.
    Demons, J.
    Workman, B.
    Wood, E.
    Satterfield, S.
    Lockery, J. E.
    Shah, R. C.
    Radziszewska, B.
    Thomas, A.
    Gill, G.
    Jackson, C.
    Kidd, M.
    Russell, G.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2013, 36 (02) : 555 - 564
  • [7] FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY
    HENNEKENS, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) : 129 - 135
  • [8] Jeffreys Diarmuid., 2004, ASPIRIN REMARKABLE S
  • [9] Miner J, 2007, TEX HEART I J, V34, P179
  • [10] AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update - Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases
    Pearson, TA
    Blair, SN
    Daniels, SR
    Eckel, RH
    Fair, JM
    Fortmann, SP
    Franklin, BA
    Goldstein, LB
    Greenland, P
    Grundy, SM
    Hong, YL
    Miller, NH
    Lauer, RM
    Ockene, IS
    Sacco, RL
    Sallis, JF
    Smith, SC
    Stone, NJ
    Taubert, KA
    [J]. CIRCULATION, 2002, 106 (03) : 388 - 391
12